Onconova Therapeutics Announces Poster Presentation at the American Society of Clinical Oncology Annual Meeting
June 05, 2023 08:00 ET
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., June 05, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel...
Onconova Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
May 15, 2023 16:18 ET
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., May 15, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel...
Onconova Therapeutics to Present at the ISID International Epidermolysis Bullosa Symposium
May 08, 2023 08:00 ET
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., May 08, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova” or “the Company”), a clinical-stage biopharmaceutical company focused on discovering and...
Onconova Therapeutics to Provide Corporate Update and Announce First Quarter 2023 Financial Results on May 15, 2023
May 04, 2023 16:05 ET
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., May 04, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova” or “the Company”), a clinical-stage biopharmaceutical company focused on discovering and...
Onconova Therapeutics and Pangea Biomed Enter into Research Collaboration to Identify Biomarkers of Response to Rigosertib
March 23, 2023 08:00 ET
|
Onconova Therapeutics, Inc.
Collaboration builds off clinical data demonstrating rigosertib’s activity against PLK1 and may inform a precision medicine approach towards rigosertib’s evaluation in new indications Collaboration...
Onconova Therapeutics Reports Full Year 2022 Financial Results and Provides Business Update
March 16, 2023 16:04 ET
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., March 16, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel...
Onconova Therapeutics to Provide Corporate Update and Announce Fourth Quarter and Full Year 2022 Financial Results on March 16, 2023
March 09, 2023 16:05 ET
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., March 09, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel...
Onconova Therapeutics Presents Preclinical Data Characterizing Rigosertib’s Mechanisms of Action at the AACR Targeting RAS Conference
March 07, 2023 08:00 ET
|
Onconova Therapeutics, Inc.
Data suggest rigosertib stimulates an anti-cancer immune response via NLRP3 activation, providing mechanistic support for clinical trials of rigosertib-checkpoint inhibitor combinations Data reveal...
Onconova Therapeutics Announces Additional Clinical Data Demonstrating Rigosertib’s Monotherapy Activity in RDEB-Associated Squamous Cell Carcinoma
February 07, 2023 08:00 ET
|
Onconova Therapeutics, Inc.
Two of two evaluable participants in an ongoing investigator-sponsored program of rigosertib in RDEB-associated squamous cell carcinoma (SCC) have achieved a complete response of all cancerous skin...
Onconova Therapeutics to Present at the 2023 Guggenheim Oncology Conference
February 01, 2023 08:00 ET
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel...